The Promise and the Hope of Gene Therapy

It has been over 30 years since visionary scientists came up with the term Gene Therapy, suggesting that for certain indications, mostly monogenic diseases, substitution of the missing or mutated gene with the normal allele via gene addition could provide long-lasting therapeutic effect to the affected patients and consequently improve their quality of life. This notion has recently become a reality for certain diseases such as hemoglobinopathies and immunodeficiencies and other monogenic diseases. However, the therapeutic wave of gene therapies was not only applied in this context but was more broadly employed to treat cancer with the advent of CAR-T cell therapies. This review will summarize the gradual advent of gene therapies from bench to bedside with a main focus on hemopoietic stem cell gene therapy and genome editing and will provide some useful insights into the future of genetic therapies and their gradual integration in the everyday clinical practice.

Automated summary

Gene therapy, proposed by visionary scientists over 30 years ago, has shown success in treating certain monogenic diseases. With the introduction of CAR-T cell therapies, gene therapy has expanded to treat a broader range of diseases. The integration of gene therapy into everyday clinical practice is expected to be gradual and impactful.